Cancer Discov. 2017 Jan;7(1):OF5. doi: 10.1158/2159-8290.CD-NB2016-140. Epub 2016 Nov 9.
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation. Objective, durable responses occurred in 38% of patients, and the side effects were less severe than with chemotherapy. The researchers have started a second trial for patients with glioma and other BRAF-mutant tumor types, this time evaluating dabrafenib combined with trametinib.
一项 I/II 期临床试验表明，达拉非尼可使携带 BRAF V600E 突变的儿童的低级别胶质瘤缩小或稳定。38%的患者出现了客观、持久的应答，且副作用较化疗轻。研究人员已开始针对患有胶质瘤和其他 BRAF 突变肿瘤类型的患者进行第二项试验，此次试验评估达拉非尼联合曲美替尼的效果。
